Journal article
Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).
Abstract
422
Background: The CELESTIAL, RESORCE, and REACH-2 trials showed survival benefit of C, Reg, and Ram, respectively, when given after S to HCC patients. However, strict eligibility criteria (SEC) may limit generalizability. In clinical practice, modified eligibility criteria (MEC) may be used to offer treatments to select patients with slightly worse performance status (ECOG 2) or limited liver dysfunction (Child-Pugh (CP) …
Authors
Fung AS; Tam VC; Meyers DE; Sim H-W; Knox JJ; Zaborska VO; Davies JM; Ko Y-J; Batuyong E; Cheung WY
Journal
Journal of Clinical Oncology, Vol. 37, No. 4_suppl, pp. 422–422
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 1, 2019
DOI
10.1200/jco.2019.37.4_suppl.422
ISSN
0732-183X